Videos

Developing pain medication with fewer side effects 

3 December 2021

Dr. Ken Ng, a professor at the University of Windsor and adjunct professor at the University of Calgary (UCalgary), and Sam Carr, a PhD student from UCalgary, have been working with Dr. Peter Facchini’s group at UCalgary to better understand how natural opiates are produced. The team has narrowed their focus on one enzyme in the last stage of […]

Closing drug development gaps with new clinical prediction AI 

1 December 2021

Quris, an artificial intelligence (AI) company in the pharmaceutical industry, has launched a clinical prediction AI platform to predict which drug candidates will safely work in humans. This will improve efficacy and cut drug development costs.   What do they do?  Quris uses AI-powered miniaturised “patients-on-a-chip” to avoid the risks and costs of failed clinical trials and eliminate […]

Listicle: Experts on the differences between FDA and EMA regulations

6 October 2021

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant, Principal Consultant at Pharmacovigilance Systems Consulting & Board advisor to Arriello, and Judi Sills, JM Sills Consulting & Board advisor to Arriello, highlight the main differences between US and EU requirements, and advise on […]

Protein-protein Interactions Using NanoBRET Technology

20 August 2021

In this video, Dr Gary Allenby, CEO Aurelia Bioscience, describes a scientific poster on ‘Protein-protein Interactions Using NanoBRET Technology’. Historically, only solution-based assays were used to screen compounds in PPI, but a more physiological approach is to examine the interaction in living cells. However, there are very few commercially available technologies that can actually do […]

Video: Micro Tissues on Electrospun Scaffolds

29 July 2021

In this video, Dr Gary Allenby, CEO Aurelia Bioscience, describes a scientific poster on ‘Magnetic Electrospun Micro-fibre Scaffold Assemblies: Examples of their use for 3-Dimensional Cell-Based Screening Applications’. How the technology works: Aurelia Bioscience has developed a 3-D micro-tissue system from electrospun material that can be used in conjunction with well plates for higher throughput […]

The gel-free, blot-free, hands-free reinvention of western blotting

22 June 2021

Aurelia Bioscience, a Nottingham, UK based pre-clinical Contract Research Organisation (CRO) has produced a video to explain the functioning of WES and JESS – two highly reproducible, capillary based, automated western blot instruments from ProteinSimple: Whilst traditional western blotting typically runs 10-20 samples in three to five hours and requires 24-48 hours to produce results; […]

Video: Re-energise your kinase discovery programme

9 June 2021

Using Promega’s NanoBRET technology, scientists at Aurelia Bioscience have implemented intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells. Advantages of this technique include examination of compound binding to target kinases at physiological ATP concentrations, expression of full-length kinase target in cells, disruption of cells (with digitonin) […]

C. elegans: a natural model for developing therapies to slow ageing

11 May 2021

Ageing is a complex and heterogeneous process and is best studied using natural models of ageing in whole organisms and large test populations. C. elegans is a proven model in many fields of biology including ageing, where major breakthroughs have occurred by identifying mutants and interventions that increase lifespan. To evaluate and develop therapies that […]

Meet Ulysses, the fully automated drug discovery platform

6 April 2021

Welcome to the Future of Drug Discovery. Welcome to Arctoris from Arctoris on Vimeo. Arctoris is a global platform company headquartered in Oxford, UK that is transforming drug discovery by combining robotics and AI. Arctoris developed and operates Ulysses, a fully automated drug discovery platform. Ulysses has been created to address fundamental problems with conventional […]

NanoBRET technology enables the study of the interaction of compounds

1 April 2021

Aurelia Bioscience is a pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have experience developing new and innovative bio-assays for different target classes using technologies to deliver client projects in a timely, efficient and cost-effective manner. Using Promega’s NanoBRET technology, Aurelia Bioscience has implemented intracellular kinase […]

Next »